拓新药业(301089)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301089 拓新药业

交易中 12-17 14:53:15

{"stockData":{"symbol":"301089","market":"SZ","secType":"STK","nameCN":"拓新药业","latestPrice":28.41,"timestamp":1765954395000,"preClose":28.3,"halted":0,"volume":2322657,"delay":0,"changeRate":0.0039,"floatShares":90976299,"shares":127000000,"eps":-0.3746,"marketStatus":"交易中","change":0.11,"latestTime":"12-17 14:53:15","open":28.3,"high":28.6,"low":27.96,"amount":65869200,"amplitude":0.0226,"askPrice":28.41,"askSize":149,"bidPrice":28.4,"bidSize":24,"shortable":0,"etf":0,"ttmEps":-0.3746,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1765954800000},"marketStatusCode":2,"adr":0,"adjPreClose":28.3,"symbolType":"stock","openAndCloseTimeList":[[1765935000000,1765942200000],[1765947600000,1765954800000]],"highLimit":31.13,"lowLimit":25.47,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":126544500,"isCdr":false,"pbRate":2.35,"roa":"--","roe":"--","epsLYR":-0.16,"committee":-0.419162,"marketValue":3595000000,"turnoverRate":0.0255,"status":0,"floatMarketCap":2585000000},"requestUrl":"/m/hq/s/301089/tweets","defaultTab":"tweets","newsList":[{"id":"2590073593","title":"拓新药业：截至2025年12月10日股东户数19,015户","url":"https://stock-news.laohu8.com/highlight/detail?id=2590073593","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590073593?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:15","pubTimestamp":1765440914,"startTime":"0","endTime":"0","summary":"证券之星消息，拓新药业(301089)12月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问一下：截止12月10日的股东人数是多少？拓新药业回复：截至2025年12月10日，公司股东户数19,015户。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100022099.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301089"],"gpt_icon":0},{"id":"2589850360","title":"拓新药业：子公司规模化生产利巴韦林原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2589850360","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589850360?lang=zh_cn&edition=full","pubTime":"2025-12-05 11:33","pubTimestamp":1764905634,"startTime":"0","endTime":"0","summary":"证券之星消息，拓新药业12月05日在投资者关系平台上答复投资者关心的问题。针对当前国内流感高发的公共卫生需求，公司全资子公司新乡制药，规模化稳定生产供应利巴韦林原料药。公司现有原料药的充足供应，为下游制剂企业生产流感治疗药物提供了关键保障，有力地支持了市场在流感高发期的用药需求，有助于缓解相关压力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500013255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301089","BK0239"],"gpt_icon":0},{"id":"2588059529","title":"拓新药业（301089）披露召开2025年第三次临时股东会通知，12月02日股价下跌0.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588059529","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588059529?lang=zh_cn&edition=full","pubTime":"2025-12-02 22:13","pubTimestamp":1764684829,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘，拓新药业报收于33.76元，较前一交易日下跌0.71%，最新总市值为42.72亿元。该股当日开盘34.08元，最高34.09元，最低33.32元，成交额达1.19亿元，换手率为3.87%。近日，拓新药业发布公告称，公司将于2025年12月18日召开2025年第三次临时股东会，会议由董事会召集，现场会议时间为当日9:00，网络投票时间为同日9:15至15:00。股权登记日为2025年12月15日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200039500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301089","BK0239"],"gpt_icon":0},{"id":"2585468952","title":"拓新药业(301089)11月20日股东户数1.9万户，较上期增加2.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585468952","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585468952?lang=zh_cn&edition=full","pubTime":"2025-11-24 17:52","pubTimestamp":1763977975,"startTime":"0","endTime":"0","summary":"证券之星消息，近日拓新药业披露，截至2025年11月20日公司股东户数为1.9万户，较11月10日增加509.0户，增幅为2.75%。在化学制药行业个股中，拓新药业股东户数低于行业平均水平，截至11月20日，化学制药行业平均股东户数为3.44万户。从股价来看，2025年11月10日至2025年11月20日，拓新药业区间跌幅为1.75%，在此期间股东户数增加509.0户，增幅为2.75%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400022900.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301089","BK0239"],"gpt_icon":0},{"id":"2583057158","title":"拓新药业（301089）公司公告补选独立董事，11月14日股价上涨1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583057158","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583057158?lang=zh_cn&edition=full","pubTime":"2025-11-14 17:34","pubTimestamp":1763112894,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，拓新药业报收于34.47元，较前一交易日上涨1.62%，最新总市值为43.62亿元。该股当日开盘33.85元，最高35.18元，最低33.66元，成交额达2.79亿元，换手率为8.84%。近日，拓新药业发布公告称，公司于2025年11月13日召开2025年第二次临时股东会，审议通过关于独立董事任期届满辞职暨补选独立董事的议案。根据公告，董红杰女士、杨德杰先生当选为第五届董事会独立董事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400028390.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301089","BK0239"],"gpt_icon":0},{"id":"2582348791","title":"拓新药业：截至2025年11月10日股东户数18,538户","url":"https://stock-news.laohu8.com/highlight/detail?id=2582348791","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582348791?lang=zh_cn&edition=full","pubTime":"2025-11-12 11:36","pubTimestamp":1762918588,"startTime":"0","endTime":"0","summary":"证券之星消息，拓新药业(301089)11月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问一下：截止11月10日股东人数是多少？谢谢拓新药业回复：截至2025年11月10日，公司股东户数18,538户。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200014569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301089"],"gpt_icon":0},{"id":"2580645812","title":"拓新药业：截至2025年10月31日股东户数18,696户","url":"https://stock-news.laohu8.com/highlight/detail?id=2580645812","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580645812?lang=zh_cn&edition=full","pubTime":"2025-11-03 16:00","pubTimestamp":1762156827,"startTime":"0","endTime":"0","summary":"证券之星消息，拓新药业(301089)11月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问一下10月31日的股东人数是多少谢谢拓新药业回复：截至2025年10月31日，公司股东户数18,696户。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300018264.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301089","BK0239"],"gpt_icon":0},{"id":"2579597365","title":"拓新药业（301089）披露补选独立董事议案，10月29日股价下跌2.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579597365","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579597365?lang=zh_cn&edition=full","pubTime":"2025-10-29 17:46","pubTimestamp":1761731208,"startTime":"0","endTime":"0","summary":"截至2025年10月29日收盘，拓新药业报收于31.31元，较前一交易日下跌2.16%，最新总市值为39.62亿元。该股当日开盘31.68元，最高32.08元，最低31.25元，成交额达1.13亿元，换手率为3.93%。近日，拓新药业发布公告称，公司将于2025年11月13日上午9:00召开2025年第二次临时股东会，会议将审议《关于公司独立董事任期届满辞职暨补选独立董事的议案》。股权登记日为2025年11月10日，现场会议登记时间为2025年11月11日，股东可通过现场、信函或电子邮件方式登记。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900037411.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301089","BK0239"],"gpt_icon":0},{"id":"2579995215","title":"图解拓新药业三季报：第三季度单季净利润同比下降1258.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579995215","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579995215?lang=zh_cn&edition=full","pubTime":"2025-10-29 03:18","pubTimestamp":1761679102,"startTime":"0","endTime":"0","summary":"证券之星消息，拓新药业2025年三季报显示，公司主营收入2.72亿元，同比下降16.64%；归母净利润-3016.11万元，同比下降1036.53%；扣非净利润-3594.28万元，同比下降247.54%；其中2025年第三季度，公司单季度主营收入8965.38万元，同比下降16.21%；单季度归母净利润-1188.05万元，同比下降1258.62%；单季度扣非净利润-1373.52万元，同比下降478.34%；负债率9.89%，投资收益303.58万元，财务费用-6.59万元，毛利率29.36%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900003424.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301089"],"gpt_icon":0},{"id":"2577961915","title":"10月24日拓新药业现1笔折价18.57%的大宗交易 合计成交3322.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2577961915","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577961915?lang=zh_cn&edition=full","pubTime":"2025-10-24 17:01","pubTimestamp":1761296479,"startTime":"0","endTime":"0","summary":"证券之星消息，10月24日拓新药业发生大宗交易，交易数据如下：大宗交易成交价格25.56元，相对当日收盘价折价18.57%，成交130万股，成交金额3322.8万元，买方营业部为广发证券股份有限公司佛山顺德南国东路证券营业部，卖方营业部为广发证券股份有限公司佛山顺德南国东路证券营业部。近三个月该股共发生1笔大宗交易，合计成交1.3万手，折价成交1笔。截至2025年10月24日收盘，拓新药业报收于31.39元，下跌1.75%，换手率2.69%，成交量2.45万手，成交额7728.57万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400029442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301089"],"gpt_icon":0},{"id":"2577838415","title":"拓新药业：截至2025年10月20日股东户数18,067户","url":"https://stock-news.laohu8.com/highlight/detail?id=2577838415","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577838415?lang=zh_cn&edition=full","pubTime":"2025-10-22 08:45","pubTimestamp":1761093910,"startTime":"0","endTime":"0","summary":"证券之星消息，拓新药业(301089)10月21日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截至2025年10月20日，公司股东人数是多少拓新药业回复：截至2025年10月20日，公司股东户数18,067户。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102200006629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301089","BK0239"],"gpt_icon":0},{"id":"2576087264","title":"拓新药业(301089.SZ)子公司产品甘磷酸胆碱通过美国Self-GRAS认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2576087264","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576087264?lang=zh_cn&edition=full","pubTime":"2025-10-17 17:02","pubTimestamp":1760691742,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拓新药业(301089.SZ)公告，公司全资子公司新乡精泉生物技术有限公司(简称“精泉生物”)的产品甘磷酸胆碱，已依据美国食品药品监督管理局(FDA)的“一般认为安全”(GRAS)准则完成严格科学评价，成功获得Self-GRAS身份。公告显示，甘磷酸胆碱是人体内天然存在的胆碱化合物，同时也是大脑神经细胞膜的关键组成部分。作为一种生物利用度高的胆碱来源，其核心功效已通过广泛研究验证，具体包括：提升认知功能，为大脑正常运作提供支持以维持脑部健康，助力运动表现提升与运动后的身体恢复，以及发挥神经保护作用，为神经系统健康提供保障。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356392.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","301089"],"gpt_icon":0},{"id":"2575230483","title":"拓新药业：截至2025年10月10日股东户数17,815户","url":"https://stock-news.laohu8.com/highlight/detail?id=2575230483","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575230483?lang=zh_cn&edition=full","pubTime":"2025-10-14 09:12","pubTimestamp":1760404341,"startTime":"0","endTime":"0","summary":"证券之星消息，拓新药业(301089)10月13日在投资者关系平台上答复投资者关心的问题。投资者提问：请问一下：截止10月10日的股东人数是多少？谢谢拓新药业回复：截至2025年10月10日，公司股东户数17,815户，感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101400032638.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301089"],"gpt_icon":0},{"id":"2571829843","title":"股市必读：拓新药业(301089)股东户数1.65万户，较上期减少26.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2571829843","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571829843?lang=zh_cn&edition=full","pubTime":"2025-09-29 02:34","pubTimestamp":1759084455,"startTime":"0","endTime":"0","summary":"截至2025年9月26日收盘，拓新药业报收于30.3元，下跌1.3%，换手率1.55%，成交量1.41万手，成交额4289.59万元。交易信息汇总资金流向9月26日主力资金净流出617.7万元；游资资金净流入94.16万元；散户资金净流入523.54万元。股本股东变化股东户数变动近日拓新药业披露，截至2025年9月19日公司股东户数为1.65万户，较7月31日减少6016.0户，减幅为26.77%。户均持股数量由上期的5631.0股增加至7689.0股，户均持股市值为24.09万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092900000972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301089"],"gpt_icon":0},{"id":"2570051814","title":"拓新药业连亏一年半 2021上市超募1.48亿中天国富保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2570051814","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570051814?lang=zh_cn&edition=full","pubTime":"2025-09-25 11:22","pubTimestamp":1758770530,"startTime":"0","endTime":"0","summary":"中国经济网北京9月25日讯 拓新药业 2025年半年报显示，报告期内，公司实现营业收入1.82亿元，同比减少16.85%；归属于上市公司股东的净利润-1828.05万元；归属于母公司所有者的扣除非经常性损益的净利润-2220.76万元；经营活动产生的现金流量净额-2301.46万元。　　拓新药业发行费用合计5869.09万元，其中保荐机构、主承销商中天国富证券有限公司获得保荐及承销费4504.65万元。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202509/25/20250925158338.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202509/25/20250925158338.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20250925/31671892.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["301089","BK0239"],"gpt_icon":0},{"id":"2567454113","title":"拓新药业最新公告：全资子公司药物研究院获CNAS实验室认可证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2567454113","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567454113?lang=zh_cn&edition=full","pubTime":"2025-09-15 18:31","pubTimestamp":1757932299,"startTime":"0","endTime":"0","summary":"拓新药业(301089.SZ)公告称，公司全资子公司河南省核苷药物研究院有限公司收到中国合格评定国家认可委员会授予的实验室认可证书。该证书表明药物研究院具备按照国家标准开展检测的能力，获得国家及国际认可，对提升公司综合竞争力和推动可持续高质量发展具有促进作用。此次实验室认可证书的获得预计不会对公司当期经营业绩产生重大影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091500026481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301089"],"gpt_icon":0},{"id":"2565956394","title":"拓新药业：聚焦抗肿瘤抗病毒赛道强化系列化产品集群竞争优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2565956394","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565956394?lang=zh_cn&edition=full","pubTime":"2025-09-05 20:52","pubTimestamp":1757076722,"startTime":"0","endTime":"0","summary":"证券之星消息，拓新药业09月04日在投资者关系平台上答复投资者关心的问题。拓新药业回复：公司主要产品胞磷胆碱钠、利巴韦林等原料药，胞嘧啶、5-氟胞嘧啶、阿糖腺苷等医药中间体，主要涉及抗病毒、抗肿瘤、神经系统用药领域。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090500037671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301089","BK0239"],"gpt_icon":0},{"id":"2562477319","title":"股市必读：拓新药业中报 - 第二季度单季净利润同比下降282.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562477319","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562477319?lang=zh_cn&edition=full","pubTime":"2025-08-28 05:34","pubTimestamp":1756330460,"startTime":"0","endTime":"0","summary":"截至2025年8月27日收盘，拓新药业报收于32.59元，下跌5.78%，换手率7.89%，成交量7.17万手，成交额2.42亿元。股本股东变化股东户数变动近日拓新药业披露，截至2025年7月31日公司股东户数为2.25万户，较7月18日增加1610.0户，增幅为7.72%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082800004912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301089"],"gpt_icon":0},{"id":"2562759331","title":"图解拓新药业中报：第二季度单季净利润同比下降282.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562759331","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562759331?lang=zh_cn&edition=full","pubTime":"2025-08-27 02:02","pubTimestamp":1756231355,"startTime":"0","endTime":"0","summary":"证券之星消息，拓新药业2025年中报显示，公司主营收入1.82亿元，同比下降16.85%；归母净利润-1828.05万元，同比下降927.39%；扣非净利润-2220.76万元，同比下降178.74%；其中2025年第二季度，公司单季度主营收入8490.51万元，同比下降23.12%；单季度归母净利润-1471.58万元，同比下降282.46%；单季度扣非净利润-1625.49万元，同比下降121.89%；负债率10.13%，投资收益170.3万元，财务费用-10.15万元，毛利率31.21%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082700002429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301089"],"gpt_icon":0},{"id":"2560900577","title":"拓新药业股价上涨1.92% 盘中快速反弹成交2.92亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2560900577","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560900577?lang=zh_cn&edition=full","pubTime":"2025-08-18 20:41","pubTimestamp":1755520913,"startTime":"0","endTime":"0","summary":"截至2025年8月18日15时29分，拓新药业股价报36.03元，较前一交易日上涨1.92%。当日开盘价为35.35元，最高触及36.70元，最低下探35.06元，成交额达2.92亿元，换手率为8.89%。拓新药业属于化学制药行业，业务涵盖原料药及医药中间体的研发、生产和销售。公司产品涉及抗病毒、抗肿瘤等领域，市场覆盖国内外。消息面上，8月18日早盘，拓新药业股价在5分钟内快速反弹，涨幅超过2%，显示短期市场交投活跃。资金流向方面，8月18日主力资金净流出315.03万元，近五日累计净流出3516.55万元。风险提示：股市有风险，投资需谨慎。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/18204152512123.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","301089"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765954397260,"stockEarnings":[{"period":"1week","weight":-0.1022},{"period":"1month","weight":-0.179},{"period":"3month","weight":-0.129},{"period":"6month","weight":-0.0912},{"period":"1year","weight":-0.1372},{"period":"ytd","weight":0.0039}],"compareEarnings":[{"period":"1week","weight":-0.0217},{"period":"1month","weight":-0.0415},{"period":"3month","weight":-0.0133},{"period":"6month","weight":0.1376},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.1411}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"拓新药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"19015人(较上一季度减少4.99%)","perCapita":"4784股","listingDate":"2021-10-27","address":"河南省新乡市红旗区高新区科隆大道515号","registeredCapital":"12654万元","survey":"　　拓新药业集团股份有限公司是集化学合成、生物发酵核苷（酸）类原料药及医药中间体的研发、生产及销售为一体的高新技术企业。主要产品有嘧啶系列、嘌呤系列、核苷酸系列、核苷系列等多个系列核苷（酸）类产品，包括胞磷胆碱钠、利巴韦林、肌苷、阿昔洛韦、胞嘧啶、5-氟胞嘧啶、胞苷等原料药及医药中间体，主要涵盖抗病毒、抗肿瘤和神经系统用药领域。公司始终将“研发创新”作为核心战略，高度重视产品研发投入和研发能力的提高，已建立了“河南省博士后研发基地”、“国家博士后科研工作站”，并荣获“国家高技术产业示范工程”、“河南省高新技术特色产业基地首批骨干企业”、“河南省企业技术中心”、“河南省核苷工程技术研究中心”等多项荣誉称号。此外，还获得了河南省科学技术进步一等奖、国家科学技术进步二等奖等重大科技奖项，并有多项产品入选“国家重点新产品”、“国家火炬计划项目”。","listedPrice":19.11},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"拓新药业(301089)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供拓新药业(301089)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"拓新药业,301089,拓新药业股票,拓新药业股票老虎,拓新药业股票老虎国际,拓新药业行情,拓新药业股票行情,拓新药业股价,拓新药业股市,拓新药业股票价格,拓新药业股票交易,拓新药业股票购买,拓新药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"拓新药业(301089)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供拓新药业(301089)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}